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Highlights 
 
x Health state utilities are key parameters in cost utility analysis. In the absence of 
health related quality of life (HRQoL) data collected directly from clinical trials, 
published literature are relied upon for health utilities estimates. 
x The review found few studies that reported preference-based health utilities in 
children with asthma. There is also a lack of robust estimates on utility decrement 
associated with asthma exacerbation in children. 
x Future studies in children with asthma are encouraged to incorporate HRQoL data 
collection into the study design. 
x This review also serves as an example on how health utilities are searched, identified 
and critically appraised for appropriateness to be used in an economic model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
Background: 
Asthma exacerbations affect quality of life for children with asthma. A cost-utility analysis 
was performed alongside the PLEASANT clinical trial to assess the cost-effectiveness of a 
letter intervention in preventing and lessening exacerbations in school-aged children at the 
start of a new school term. The economic analysis relied on published literature for health 
utilities estimates as no patient reported outcome measures were collected in the trial.  
 
Objective: 
To identify preference-based utility values for children with day-to-day asthma symptoms 
(baseline utility) and children experiencing an asthma exacerbation, and to review the 
appropriateness of the utility values to be used in the PLEASANT economic analysis.  
 
Methods: 
A systematic review was performed in five electronic databases (Ovid MEDLINE, The 
Cochrane Library, EMBASE, ECONLIT and SCHARR Health Utilities Database) up to 5th 
July 2014 to identify studies that report preference-based utility values in children with 
asthma. Results were summarised narratively and utility data were assessed for quality, 
relevance to the economic analysis and compliance with the NICE reference case.  
 
Results: 
A total of 927 studies were identified from the search and 14 studies which met the inclusion 
criteria were included. Health utilities were elicited using various outcome measurements. 
EQ-5D was used in 5 studies (35.7%), HUI, PAHOM and direct valuation using vignettes 
were each reported in 2 studies (14.3%). Three (21.4%) studies estimated utility values from 
mapping between condition specific measures and the EQ-5D. None of the studies directly 
measured health utilities in children with asthma exacerbation using a preference-based 
measure.  
 
Conclusions: 
There is a lack of robust estimates on utility decrement in children with asthma exacerbation. 
Future studies in children with asthma should incorporate collection of health state utilities 
into the study design, taking into account the ethical and methodological considerations of 
quality-of-life assessment during exacerbation.  
 
FUNDING: The PLEASANT study was funded by NIHR Health Technology Assessment 
Programme (project number 11/01/10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.0   Introduction 
 
A public health preventive strategy of a letter intervention sent to parents prior to the start of 
a new school year, to promote medication adherence was assessed in the Preventing and 
Lessening Exacerbation of Asthma in School-age children Associated with a New Term 
(PLEASANT) cluster randomised controlled trial. A cost utility analysis was performed 
alongside PLEASANT. Patient level data were obtained from CPRD which comprised of 
longitudinal medical records from primary care (1). This efficient design of the study allows 
a large amount of resource use to be captured without the need to collect information from 
practice sites. However, preference-based utility measures such as EQ-5D were not collected 
via CPRD. Given the absence of utility data collected directly from patients, a systematic 
review was performed to identify health state utility values for children with and without 
asthma exacerbation. 
 
This review aimed to identify preference-based utility values for children with day-to-day 
asthma symptoms (baseline utility) and children experiencing an asthma exacerbation, and to 
review the appropriateness of the utility values for the PLEASANT economic analysis. 
 
2.0 Methods 
 
2.1 Scoping  
A scoping search was conducted to establish the likely quantity and relevance of published 
literature. This was done by searching the MEDLINE, Cochrane HTA and NHS EED 
databases using a limited number of population terms in addition to a search filter for quality 
of life. It was found that there was a lack of utility data derived from EQ-5D in children with 
asthma. Although EQ-5D is the preferred outcome measure, the standard version of EQ-5D is 
not designed to be used in children. EQ-5D-Youth is available for children and adolescents, 
but there is not yet a validated UK tariff. In view of this, the NICE reference case states that 
other validated preference-based measures developed for children may be used instead, but 
does not specify the preferred quality of life instrument (2). Therefore, a broad approach was 
taken in the search to identify utility values derived from EQ-5D, as well as other preference-
based utility measures. EQ-5D values estimated from mapping studies were also considered.  
 
2.2  Search strategy 
 
2.2.1 Search terms 
Both free text and MESH headings pertaining to children, asthma and asthma exacerbation 
were used in the search (see Appendix 1: Full search strategy 
). The InterTASC Information SpeciaOLVWV¶6XE-Group (ISSG) search filter was used to filter 
studies that report health-related quality of life (see Appendix 2: Quality of life filter 
). The filter was adapted to include a newly-developed preference-based utility measure for 
children, Child Health Utility Index 9D (3), as well as other preference-based measures in 
asthmatic children, such as the Asthma Symptom Utility Index. Full search terms for this 
review are presented in Appendices 1 and 2. 
 
2.2.2 Search limit 
To increase sensitivity, the search was not limited by language, publication type, publication 
dates or study design.  
 
2.2.3 Sources searched 
The following clinical and economic databases were searched: 
x Ovid MEDLINE (In-Process & Other Non-Indexed Citations) (1946 to 5th July, 2014) 
x The Cochrane Library (includes Cochrane Database of Systematic Review (CDSR),  
NHS Economic Evaluation Database (NHS EED) and Health Technology Assessment 
(HTA) database) (up to 5th  July, 2014) 
x EMBASE (1974 to 5th July, 2014) 
x ECONLIT (1886 to 5th July, 2014) 
x SCHARR Health Utilities Database (up to 5th July, 2014). 
In addition to the electronic database search, reference lists of the retrieved papers were 
screened for relevant papers. 
 
2.3 Inclusion and exclusion criteria 
The inclusion and exclusion criteria for the review are summarised in Table 1. Systematic 
reviews and protocols were not included, but were used to identify relevant papers. 
Modelling studies were examined to determine the source of utility values used. Modelling 
studies which described utility data not reported elsewhere were included in the review. Non-
English papers with English language abstracts were initially included but were excluded at 
full-text when English translations were not obtainable.   
 
Table 1 Review inclusion and exclusion criteria 
Criteria Inclusion Exclusion 
Population x Children with asthma 
x Population with mixed age 
groups but including some 
children 
x Asthmatic patients aged 18 
years and above 
x Non-asthma patients 
Intervention  x Studies that only presented 
the utility change associated 
with a particular intervention 
Outcomes x Utility values from 
preference-based measures 
 
x Non preference-based utility 
scores unless mapping to 
EQ-5D was performed 
x Studies which did not 
publish utility data 
Publication type  x Qualitative study 
x Letters 
x Editorials 
x Case reports / case series 
x Systematic review 
x Protocols 
Language x English published papers x Non-English published 
papers 
 
 
 
2.4 Selection of studies 
In the first stage of study selection, titles and abstract of the searched results were screened 
against the inclusion / exclusion criteria. Full articles were assessed if titles and abstracts 
were unclear. All studies identified during screening of titles and abstracts were further 
screened at full text.  
 
2.5 Quality assessment 
Quality assessment of articles in this review followed the criteria (sample size, number loss at 
follow up and handling of missing data) recommended by Papaioannou et al. (4)  in the 
Decision Support Unit Technical Support Document on the identification, review and 
synthesis of health state utility values from the literature. 
 
2.6 Data Extraction 
Data extracted comprised of characteristics of study population, study design and details of 
outcome measurements (descriptive system, tariff used, method of valuation, time of 
measurement, mean utility data and other relevant measures). 
 
2.7 Selection of utility data for use in the PLEASANT economic analysis 
Selection of utility data to use in the PLEASANT economic analysis was based on i) quality 
of the study, ii) the relevance of utility data to the population and health states in 
PLEASANT, (iii) the extent to which the measurement method was in accordance with the 
NICE reference case. 
 
3.0 Results  
A total of 927 studies were retrieved from the database search and reference tracking. After 
removal of duplicates, 683 studies were screened at titles and abstract. A total of 659 studies 
were excluded at this stage. The most common reasons for exclusion were that the population 
was aged over 18 years, that utility values were not reported or that the values reported were 
not preference-based utility values (Appendix 3). Subsequently, 24 papers were screened at 
full-text and 10 papers were excluded with reasons given for each paper in Appendix 4. 
Finally, 14 papers were included in this review. Figure summarises the search process of this 
review. 
 
Study characteristics for the included studies are summarised in Table . The study 
populations are summarised in Table 2 and methods used to measure health-related quality of 
life (HRQoL) are summarised in Table 3. Details regarding study quality are provided in  
Table 4. Details regarding the suitability of the studies for use in the economic model, based 
on the criteria described above, are provided in Table 5. 
 
Figure 1: Flow diagram of search process   
Table 2: Characteristics of included studies 
No Authors, (year) Country Study Design Total 
participants 
Duration Intervention Control Primary outcome(s) 
1 Willems et al. (5) Netherlands Economic evaluation 
alongside an RCT 
109 (56 aged 
under 18) 
1 year Nurse-led 
telemonitoring  
Usual care Cost per QALY 
2 Powell et al. (6) UK Multi-centre, double 
blind, RCT 
508 children 1 month Nebulised magnesium 
sulphate 
Usual care Asthma severity score 
1 hour after treatment 
3 Price et al. (7) UK Single blind, RCT, 
pragmatic 
687 (mixed age 
group, 12-80 
years) 
2 years Leukotriene receptor 
antagonist (step 2) 
As above plus ICS (step 
3) 
ICS ( step 2), 
 ICS+ LABA 
( step 3) 
Changes in Mini 
AQLQ  
4 Brusselle et al. 
(8) 
Belgium Cohort 158 (mixed age 
group) 
52 weeks Omalizumab N/A [single arm 
study] 
Clinical effectiveness 
(asthma symptoms, 
lung function, 
HRQoL) and safety of 
omalizumab 
5 Chiou et al. (9) USA Outcome measure was 
used in the baseline 
assessment of  an RCT 
Utility 
measurement 
was performed 
on a sample of 
72 children 
from the RCT 
Baseline utility 
measurement 
Environmental 
intervention 
Placebo HRQoL 
No Authors, (year) Country Study Design Total 
participants 
Duration Intervention Control Primary outcome(s) 
6 Mittmann et al. 
(10) 
Canada Cross-sectional survey 17,626 
household 
residents of 
which 229 had 
asthma 
Cross-
sectional  
None None HRQoL 
7 Juniper et al. (11) Canada Cohort 52 children 9 weeks None None Validity of outcome 
measures in children 
8 Norman et al. 
(12) 
UK Decision model,  
EQ-5D data from 
EXALT study used for 
day-to-day symptoms 
Literature based 
estimate used for 
exacerbation 
EXALT: 404 
(mixed age 
group) 
EXALT: 36 
weeks 
Omalizumab and usual 
care 
Usual care Cost per QALY 
9 Briggs et al. (13) Multinational  Economic evaluation 
of  GOAL  
(multi-national, 
double blind, RCT), 
 CSM data from 
GOAL were mapped 
onto EQ-5D 
GOAL:3,416 
(mixed age 
group) 
GOAL: 52 
weeks, model 
as weekly 
event 
Salmeterol/fluticasone Fluticasone Cost per QALY 
No Authors, (year) Country Study Design Total 
participants 
Duration Intervention Control Primary outcome(s) 
10 Doull et al. (14) Multinational Decision model, CSM 
data from GOAL  
(multi-national, 
double blind, RCT) 
were mapped onto 
EQ-5D 
GOAL:3,416 
(mixed age 
group) 
GOAL: 52 
weeks, model 
as weekly 
event 
Salmeterol/fluticasone Fluticasone Cost per QALY 
11 Rodriguez et al. 
(15) 
Colombia 
 
Decision model 
(Markov),  
utility values were 
derived from a utility 
valuation survey  
76 parents were 
involved in the 
survey 
Utility 
measured at 
one time point 
Budesonide, fluticasone, 
ciclesonide 
Beclomethasone 
dipropionate 
Cost per QALY 
12 Carroll et al. (16) USA Cross-sectional 4,016  parents, 
each valued 3 
of 29 health 
states 
(~415 
valuations per 
health state) 
Duration of 
recruitment : 2 
years  
HRQoL 
measurement 
was performed 
at a time point 
None None Utility values 
13 Brown et al. (17) Multinational Decision 
model(Markov), CSM 
data from 
ETOPA  
(open-label trial) 
ETOPA: 312 
(mixed age 
group) 
1 year Omalizumab and BSC BSC Cost per QALY 
No Authors, (year) Country Study Design Total 
participants 
Duration Intervention Control Primary outcome(s) 
were mapped onto 
EQ-5D 
14 Gerald et al. (18) USA Decision model 
(decision tree and 
Markov) 
Utility data 
based on study 
by Chiou et al. 
(2005) 
Time horizon: 
1 year,  
cycle length: 1 
day 
Four school based 
asthma screening 
strategies 
Status quo Cost per QALY  
CSM: Condition specific measure, RCT: randomised controlled trial, HRQoL: health-related quality of life, BSC: best supportive care, MgSO4: magnesium sulphate, 
ICS: inhaled corticosteroids, LABA: long acting beta2-agonist, AQLQ: Asthma Quality of Life Questionnaire 
 
Table 2: Population of included studies 
Authors, (year) Disease type Severity/stage Age, Mean(sd) Male Gender (%) Ethnicity 
Willems et al. (5) Mild to moderate asthma  
managed in outpatient care 
GINA stage I to III,  
mean FEV1% predicted for children: 
96.5 (sd 8.4) for intervention and 99.4 
(sd 11.3) for control 
7-18 years strata, intervention: 
10.57 (sd 2.1) control: 10.85 
(sd 2.3) 
Intervention: 
72.4%  
control: 55.6% 
Not reported 
Powell et al. (6) Acute asthma Severe acute asthma (BTS/SIGN 
definition) 
Median 4.0 (IQR 3.0±7.0), 
range: 2±16 years 
58% Not reported 
Price et al. (7) Poorly controlled asthma at 
BTS/SIGN Step 2or 3 
AC4RU0LQL$4/ Step 2: 44.74 (16.49), 
Step 3: 50.02 (15.93), range 
12-80 years 
Step 2: 162 
(49.7%),  
Step 3: 136 
(37.7%) 
98% Caucasian  
Brusselle et al. (8) Poorly controlled severe 
persistent allergic asthma 
on ICS/LABA (GINA 
definition) 
Mean FEV1%<80% predicted, 
 day and night symptoms, 
 H[DFHUEDWLRQVUHTXLULQJV\VWHPDWLF
steroid , ED or hospitalizations) in past 2 
years 
Mean 48.17 (17.18),  
range 12-83 years 
73 (46.2%) 94.9% Caucasian 
Chiou et al. (9) Diagnosed asthma Mild to severe 7-8 years (37.5%), 
9-10 years (34.7%), 
11-12 years (27.8%) 
Not reported White (15.3%), 
Asian (40.3%), 
African American 
(29.2%) 
Authors, (year) Disease type Severity/stage Age, Mean(sd) Male Gender (%) Ethnicity 
Mittmann et al. (10) Asthma generally Not reported Not reported.  
10.5% (N=1,847) of total 
respondents were under 19 
years 
8,058 (45.7%) but 
data was not 
stratified to age 
Caucasian 
Juniper et al. (11) Symptomatic asthma Mean FEV1% predicted: 85±16.6  
no previous exacerbation in past 2 weeks 
12.(3.1),range:7-17 years 30 (57.7%) Majority Caucasian 
Norman et al. (12) Poorly controlled severe 
persistent allergic asthma 
on high dose ICS and 
LABA with >1 severe 
exacerbations in previous 
year and FEV <80% 
predicted 
%766,*16WHS 
EXALT: FEV 40-80% predicted  
>1 severe exacerbations within previous 
year 
EXALT:  
Mean across both arms: 44.7 
range: 12-75 years 
[only 5 patients under 18 years] 
EXALT:                 
141 (35.2% ) 
 
Not reported 
Briggs et al. (13) DLDJQRVHGDVWKPD
months), no use of LABA 
or oral beta2-agonists in 
previous 2 weeks 
Uncontrolled asthma, mean FEV1 % 
predicted: ranged from 76 to 79  
SFC: stratum 1; 36.1 (15.6), 
stratum 2; 40.4 (16.4), stratum 
3; 44.1 (15.9); 
FC: stratum 1; 36.4 (15.6), 
stratum  2; 40.3 (16.6), stratum 
3; 42.7 (15.7) 
42% Not reported 
Authors, (year) Disease type Severity/stage Age, Mean(sd) Male Gender (%) Ethnicity 
Doull et al. (14) DLDJQRVHGDVWKPD
months), no use of LABA 
or oral beta2-agonists in 
previous 2 weeks 
Uncontrolled asthma, mean FEV1 % 
predicted: ranged from 76 to 79  
SFC: stratum 1; 36.1 (15.6), 
stratum 2; 40.4 (16.4), stratum 
3; 44.1 (15.9); 
FC: stratum ;1 36.4 (15.6), 
stratum 2; 40.3 (16.6), stratum 
3; 42.7 (15.7) 
42% Not reported 
Rodriguez et al. (15) Persistent asthma Mild to moderate asthma Not reported Not reported Caucasian 
Carroll et al. (16) Persistent asthma Mild to severe Not reported 1,982(49%) 
>JHQGHURISDUHQW¶V
child] 
African American 
(48%) Caucasian 
(47%) 
Brown et al. (17) Poorly controlled severe 
persistent allergic asthma 
despite high-dose ICS and 
LABA 
Subgroup of severe patients from 
ETOPA included 
 
For whole ETOPA trial:  
Omalizumab 37.5 (range: 12±
73), best supportive care: 39.3 
(range: 12±71) 
For whole ETOPA 
trial: Omalizumab 
and best supportive 
care: 58 (28.2%), 
best supportive 
care: 34 (32.1%) 
Caucasian 
Gerald et al. (18) Asthma symptom-free day 
(ASFD), symptom days, 
exacerbation recovery 
days, emergency 
department visits, and 
hospitalization days 
Intermittent, mild, moderate, severe Utility data based on study by 
Chiou et al (2005) 
Utility data based 
on study by Chiou 
et al (2005) 
Utility data based 
on study by Chiou 
et al (2005) 
Table 3: Outcome measurement and utility values in each study 
Authors, 
(year) 
Descriptive 
system  
Type  Descriptive measure 
filled by 
Population in 
valuation 
Valuation 
method  
When  
HRQoL data 
were 
obtained 
Mean, (sd) Other HRQoL 
measures 
Willems et al. 
(5) 
EQ-5D (child 
version) 
Generic  Carer(age<12),  
E\SDWLHQW 
Adult UK 
tariff (19) 
TTO Baseline, 
4 month,  
8 month,  
12 month 
7-18 years strata at baseline: 
usual care, 0.96 (0.07),  
telemonitoring, 0.92 (0.20) 
PAQLQ 
Powell et al. 
(6) 
EQ-5D  Generic  Carer of children age 
between 5 -16 years 
Adult UK 
tariff (19) 
TTO 1 month post 
exacerbation 
Exacerbation: 0.52 (based on 
mean ASS score of 5.8 mapped 
to EQ-5D 22222) 
1 month: magnesium group, 
0.86 (0.04), standard care, 0.88 
(0.04) 
PedsQL  
Price et al. (7) EQ-5D Generic  Patient Adult UK 
tariff (19) 
TTO 2 months and 
2 years 
Step 2 at baseline: Intervention 
0.795 (0.245), Control 0.830 
(0.195),  
Step 3 baseline:  
Intervention 0.780 (0.237), 
Control 0.772 (0.234) 
Mini AQLQ, 
asthma control 
questionnaire 
Brusselle et 
al. (8) 
EQ-5D Generic  Patient Belgian tariff VAS Baseline, 52 
weeks 
At baseline:0.54 (0.24) AQLQ 
Authors, 
(year) 
Descriptive 
system  
Type  Descriptive measure 
filled by 
Population in 
valuation 
Valuation 
method  
When  
HRQoL data 
were 
obtained 
Mean, (sd) Other HRQoL 
measures 
Chiou et al. 
(9) 
PAHOM Population
-specific 
measure 
Patient Adults valuing 
for children 
VAS, SG Single time 
point 
General asthma (VAS:0.7 
converted SG:0.83) 
None 
Mittmann et 
al. (10) 
HUI3 Generic Participant was 
interviewed by phone 
or in person 
HUI2 (Canada 
algorithm) 293 
parents of 
school 
children 
VAS, SG Single time 
point 
12-19 years: 0.90 (0.12) None 
Juniper et al. 
(11) 
HUI2 
(interviewer 
version) 
Generic  Children HUI2 (Canada 
algorithm) 
293 parents of 
school 
children 
VAS, SG Baseline, 
week 5 and 
week 9 
At baseline: 0.89 (0.09) (0.67±
1.00) 
PAQLQ, Feeling 
thermometer, 
direct valuation 
via SG 
Norman et al. 
(12) 
EQ-5D Generic   Patients Not stated Not stated 31 weeks  31 weeks:  
standard care 0.719 (0.026), 
 omalizumab 0.767 (0.02) 
AQLQ 
Briggs et al. 
(13) 
Mapped EQ-
5D from  
AQLQ 
Mapping 
of CSM to 
EQ-5D 
Patient Valuation 
population not 
reported 
Valuation 
method not 
reported 
Baseline, 12, 
24, 36, and 52 
weeks 
Totally Controlled: 0.946 (SE 
0.011), well-controlled: 0.900  
(SE 0.011),  not well controlled: 
0.842 (SE 0.011), exacerbation: 
AQLQ 
Authors, 
(year) 
Descriptive 
system  
Type  Descriptive measure 
filled by 
Population in 
valuation 
Valuation 
method  
When  
HRQoL data 
were 
obtained 
Mean, (sd) Other HRQoL 
measures 
0.729 (SE 0.013) 
Doull et al. 
(14) 
Mapped EQ-
5D from  
AQLQ 
Mapping 
of CSM to 
EQ-5D 
Patient Valuation 
population not 
reported 
Valuation 
method not 
reported 
Baseline, 12, 
24, 36, and 52 
weeks 
Symptom free: 0.97 (0.014), 
with symptoms: 0.85 (0.015) 
AQLQ 
Rodriguez et 
al. (15) 
Direct 
valuation using 
vignettes 
Direct 
valuation 
N/A Parents SG Single time 
point 
No symptoms (0.989), symptom 
no exacerbation (0.705) and 
asthma exacerbation (0.275) 
None 
Carroll et al. 
(16) 
Direct 
valuation using 
vignettes 
Direct 
valuation 
N/A Parents TTO, SG Single time 
point 
SG: mild intermittent 0.91 
(0.18),  mild persistent 0.90 
(0.18),  moderate persistent 0.88 
(0.18),  severe persistent asthma 
0.83 (0.21), 10 day 
hospitalization 0.94 (0.14)  
TTO: mild intermittent 0.91 
(0.17),  mild persistent 0.91 
(0.18),  moderate persistent 0.91 
(0.15),  severe persistent asthma 
0.85 (0.20), 10 day 
hospitalization: 0.95 (0.15) 
None 
Authors, 
(year) 
Descriptive 
system  
Type  Descriptive measure 
filled by 
Population in 
valuation 
Valuation 
method  
When  
HRQoL data 
were 
obtained 
Mean, (sd) Other HRQoL 
measures 
Brown et al. 
(17) 
Mapped EQ-
5D from mini 
AQLQ 
Mapping 
of CSM to 
EQ-5D   
Patient Adult UK 
tariff  for EQ-
5D (19) 
TTO  Baseline and 
52 weeks  
Daily symptoms, baseline: best 
supportive care 0.62, 
omalizumab 0.58,  
Daily symptoms, week 52: best 
supportive care 0.65, 
omalizumab 0.82 
Mini AQLQ 
Gerald et al. 
(18) 
PAHOM Population 
specific 
measure 
N/A (utility data for 
modelled states were 
estimated by 
averaging utility 
values of PAHOM 
states) 
PAHOM: 
adults valuing 
for children 
VAS, SG N/A  ASFD 1.0 (0.98-1.0)  
Symptomatic 0.90 (0.84-0.96) 
Recovery 0.70 (0.64-0.76)  
ED 0.43 (0.37-0.49)  
Hospitalization 0.06 (0.01-0.11)  
None 
AQLQ: Asthma Quality of Life Questionnaire, EQ-5D: EuroQol-5 Dimension Questionnaire, CSM: Condition specific measure, FEV1: Forced Expiratory Volume in the 
first second, HUI2: Health Utilities Index Mark 2, HUI3: Health Utilities Index Mark 3, ICS: inhaled corticosteroid, LABA: long acting beta2-agonist, LTRA: 
Leukotriene receptor antagonist, PAHOM: Pediatric Asthma Health Outcome Measure, PAQLQ: Paediatric Asthma Quality of Life Questionnaire  3('64/ 
Pediatric Quality of Life, SF6D: Short Form 6D 
 
 Table 4: Quality assessments of included papers 
Authors, (year) Sample size Number loss at follow up Methods of handling missing data 
Willems et al. (5) 109 (mixed age 
group) 
7/109 (4 children) Data imputation by using mean for baseline score, interpolation 
between scores and last value carried forward 
Powell et al. (6) 508 children Postal survey response rate: 45%. 228 completed 
PedsQL. 89 patients aged over 5 completed EQ-5D 
questionnaires (46 in magnesium arm, 43 in placebo)  
Multiple imputation by chained equations was used to impute 
missing data. 
In under 5s the EQ-5D scores were estimated by mapping from 
the PEDSQOL scores. 
EQ-5D scores at time of exacerbation were mapped subjectively 
from ASS scores. 
 
Price et al. (7) 687 (mixed age 
group) 
Step 2: 20/326 excluded post randomisation, 
13/306 loss to follow-up but 300/306 had some data 
post-randomisation 
step 3: 9/361 excluded post randomisation, 12/352 were 
lost to follow up but 350/352 had some data post 
randomisation 
Complete data in: 218/683 patients (32%),  
less than 4 missing data out of 13 data: 514/683 (75%).                     
19% missing visit 2 EQ-5D data.  
 
Complete case analysis presented. In addition imputed case 
SUHVHQWHGXVLQJ5XELQ¶VPXOWLSOHLPSXWDWLRQ 
Brusselle et al. (8) 158 (mixed age 
group) 
Only 126 of 158 patients had baseline EQ-5D values and 
only 67 had EQ-5D data at 1 year. 
Not reported 
Authors, (year) Sample size Number loss at follow up Methods of handling missing data 
Chiou et al. (9) 72 children Not applicable Not reported 
Mittmann et al. (10) 17,626 household 
residents of which 
229 had asthma 
Not relevant as cross-sectional data Not reported 
Juniper et al. (11) 52 children None Complete datasets provided for all patients 
Norman et al. (12) EXALT: 404 
(mixed age group) 
EQ-5D scores available for 318 (79%) at 31 weeks Not reported 
Briggs et al. (13) GOAL: 3,416 
(mixed age group) 
526 withdrawals including 111 lost of follow up. 
Reasons were adverse events, withdrawal of consent, 
protocol violation, ineligible for study, data that could 
not be analysed (n=117) 
Not reported  
Doull et al. (14) GOAL: 3,416 
(mixed age group) 
526 withdrawals including 111 lost of follow up. 
Reasons were adverse events, withdrawal of consent, 
protocol violation, ineligible for study, data that were not 
able to be analysed (n=117) 
Not reported  
Rodriguez et al. (15) 76 parents Not reported Not reported 
Authors, (year) Sample size Number loss at follow up Methods of handling missing data 
Carroll et al. (16) 4,016  parents, 29 
diseases 
Not reported Not reported 
Brown et al. (17) ETOPA: 312 
(mixed age group) 
Not reported Imputation method for patient prematurely withdrawn. Event with 
zero duration was assigned if patient did not experience any event 
after 7 days of discontinuation 
Gerald et al. (18) Utility data based 
on study by Chiou 
et al (2005) 
Utility data based on study by Chiou et al (2005) Utility data based on study by Chiou et al (2005) 
 
 
 
Table 5: Relevance of studies to the PLEASANT analysis and the NICE reference case 
Authors, (year) Relevance of population Relevance of health states Instrument Measured 
from 
Tariff  Valuation 
method 
Applicability issues 
Willems et al. (5) Stratified into adults and 
children 
Baseline utility for mild-
moderate asthma patients 
EQ-5D Carer or 
children 
\HDUV 
Adult UK 
tariff (19) 
TTO EQ-5D from non-UK 
population 
Powell et al. (6) Young children Utility of severe acute 
asthma and post 
exacerbation 
EQ-5D for post 
exacerbation. 
For acute 
exacerbation, 
EQ-5D states 
were mapped to 
ASS scores 
Carer as 
proxy for  
FKLOGUHQ
years 
Adult UK 
tariff (19) 
TTO EQ-5D are preferred 
but subjective 
mapping was used to 
estimate EQ-5D from 
ASS during 
exacerbation 
Price et al. (7) Mixed age (above 12 years, 
mean age of 44.7 years in 
Step 2, 50 years in Step 3 
Baseline utility 
(uncontrolled asthma) by 
intervention arm, utility 
changes due to intervention 
EQ-5D Patient Adult UK 
tariff (19) 
TTO Utility decrement for 
exacerbations not 
reported 
Brusselle et al. 
(8) 
Population is constrained to 
severe asthma with long 
duration of asthma, older 
population (mean age 48 
years), allergic and on 
maintenance steroids 
Baseline utility of 
population with uncontrolled 
severe allergic asthma  
EQ-5D Patient Belgian 
tariff 
VAS Utility decrement for 
exacerbations not 
reported 
 
None UK Tariff VAS 
not TTO 
Authors, (year) Relevance of population Relevance of health states Instrument Measured 
from 
Tariff  Valuation 
method 
Applicability issues 
Chiou et al. (9) Children with diagnosed 
asthma of at least mild 
persistent severity 
Utility of asthma generally,  
score stratified by severity  
PAHOM Children Adult 
preference 
VAS, SG 
(converted 
from VAS) 
 Utility decrement for 
exacerbations not 
reported 
 
Mittmann et al. 
(10) 
Stratified by age 12-19 years Utility of asthma generally HUI3 Patient HUI2 
(Canadian 
algorithm) 
VAS, SG Utility decrement for 
exacerbations not 
reported 
Juniper et al. (11) Children population, 
symptomatic asthma, with 
no exacerbation in past 2 
weeks, FEV1 >80%  
predicted 
Baseline utility in general 
asthma 
HUI2 Children HUI2 
(Canadian 
algorithm) 
VAS, SG Utility decrement for 
exacerbations not 
reported 
Norman et al. 
(12) 
Poorly controlled severe 
persistent allergic asthma 
Utility of day to day 
symptoms (not exacerbation) 
EQ-5D Patients Not stated  Not stated Utility decrement for 
exacerbations not 
derived from this 
study (literature 
based estimates used) 
Authors, (year) Relevance of population Relevance of health states Instrument Measured 
from 
Tariff  Valuation 
method 
Applicability issues 
Briggs et al. (13) Mean age >30, mean FEV1  
<80% predicted, utility 
adjusted in regression to UK 
population, population 
treated with inhaled 
fluticasone  or 
salmeterol/fluticasone 
Relevant health states: 
totally controlled (TWC), 
well-controlled (WC), not 
well controlled without 
exacerbation (NWC) and 
exacerbation (X) 
Mapped EQ-5D 
from AQLQ 
Patient Not reported  Not reported Used an unpublished 
mapping algorithm 
and insufficient 
details reported to 
assess validity 
mapping method 
Doull et al. (14) Mean age >30, mean FEV1  
<80% predicted, utility 
adjusted in regression to UK 
population, population 
treated with inhaled 
fluticasone  or 
salmeterol/fluticasone 
Health states were less 
relevant than those used by 
Briggs et al (2006) as the 
exacerbation state was 
combined with other 
symptomatic states 
Mapped EQ-5D 
from AQLQ 
Patient Not reported  Not reported Used an unpublished 
mapping algorithm 
and insufficient 
details reported to 
assess validity 
mapping method 
Rodriguez et al. 
(15) 
Parents answering for 
children 
Health states were no 
symptoms, suboptimal 
control, no exacerbation and 
asthma exacerbation 
Direct valuation Parents No SG Direct valuation of 
clinical vignettes 
does not meet the 
NICE reference case 
Carroll et al. (16) Carer valuing for children 
age between 0-18 years 
Utility data for different 
asthma severity  
Direct valuation Parents No TTO, SG Direct valuation of 
clinical vignettes 
does not meet the 
NICE reference case 
Authors, (year) Relevance of population Relevance of health states Instrument Measured 
from 
Tariff  Valuation 
method 
Applicability issues 
Brown et al. (17) Poorly controlled allergic, 
severe asthma with mean 
age of 37.5-39.3 years 
Utility for day to day 
symptoms at baseline and 1 
year  
Mapped EQ-5D 
from mini 
AQLQ 
Patient Adult UK 
tariff (19) 
for EQ-5D 
TTO Utility decrement for 
exacerbations not 
derived from this 
study (literature 
based estimates used) 
Gerald et al. (18) Cohort of school children 
with asthma 
Reported health states 
related to asthma 
exacerbations 
PAHOM Estimated 
based on 
children's 
characteristi
cs 
PAHOM 
derived from 
adult 
preferences 
VAS, SG 
(SG 
converted 
from VAS) 
Health states were 
subjectively mapped 
to PAHOM state 
 
 
Six studies included UK patients, three of which were multinational studies. Three papers 
were from the USA, two were Canada-based and one each was from the Netherlands, 
Belgium and Colombia. Only studies by Juniper et al. (11), Chiou et al. (9), and Powell et al. 
(6) directly measured HRQoL in populations confined to children. Chiou et al. (9) recruited 
children aged between 7 and 12 years with diagnosed asthma of at least mild persistent 
severity, while Juniper et al. (11) studied children with symptomatic asthma with mean age of 
12 years (range 7 to 17 years) and Powell et al. (6) included children aged between 2 and 16 
years with acute severe asthma. Two studies, Rodriguez et al. (15) and Carroll et al. (16) 
elicited preferences from parents regarding health states in children. The other studies 
comprised of populations with mixed age groups. Among these studies, Mittmann et al. (10) 
and Willems et al. (5) presented HRQoL data stratified by age.  
 
The populations in the included studies differed in asthma severity and characteristics. Five 
(35.7%) studies measured HRQoL using EQ-5D. Other studies used outcome measurements, 
such as the Paediatric Asthma Health Outcome Measurement (PAHOM) (n=2, 14.3%) and 
the Health Utilities Index (n=2, 14.3%) [Mark 2 (HUI2) (n=1) and Mark 3 (HUI3) (n=1)]. 
Direct valuation using vignettes was used in two studies (14.3%). This review also included 
three (21.4%) modelling studies which estimated EQ-5D data from mapping exercises.  
 
EQ-5D is a generic preference-based measure in which the descriptive systems consist of five 
dimensions: mobility, depression/anxiety, self-care, usual activities, pain and discomfort. 
Each dimension has three levels of severity and this gives rise to 243 possible health states 
described by EQ-5D. In the UK, scoring of EQ-5D was based on time-trade off (TTO) in a 
representative sample of 2,997 adults administered using the York Measurement and 
Valuation of Health TTO protocol. Public preferences were obtained for 43 health states and 
regression was used to model data for the remaining health states. Utility score from the 
DOJRULWKPZDVDQFKRUHGDW³´IRUSHUIHFWKHDOWKDQG³´IRUa state equivalent to death (20). 
 
Willems et al. (5), Price et al. (7) and Powell et al. (6) were randomised controlled trials 
(RCTs) which elicited an EQ-5D index score using UK preferences, whereas the EQ-5D 
score in a cohort study by Brusselle et al. (8) was based on a Belgian tariff. Norman et al. 
(12) was a modelling study which used EQ-5D collected from the EXALT trial. The tariff 
used in the EXALT study is not described by Norman et al. (12), but the data is described as 
being consistent with the NICE reference case suggesting that the UK TTO valuation set was 
used. In the MAGNETIC trial, Powell et al. (6) included a population of children (n=508) 
with severe acute exacerbations, as defined by BTS/SIGN. The MAGNETIC trial was a 
prospective, double-blind, multicentre RCT in the UK, designed to compare efficacy of 
nebulised magnesium sulphate with usual care. EQ-5D and Paediatric Quality of Life 
3HGV4/ SRVWDO TXHVWLRQQDLUHV ZHUH FROOHFWHG DW RQH PRQWK SRVW-exacerbation. EQ-5D 
GDWD ZHUH REWDLQHG IRU FKLOGUHQ DJHG   \HDUV DQG ZHUH ILOOHG E\ SDUHQWV DV SUR[\ ZKLOH
3HGV4/ZHUHREWDLQed for all children and were self-completed if children were aged over 
five years. Respondents were asked to recall events in the previous four weeks while filling 
out the outcome measures. Adult UK tariff by Dolan (19) was applied to EQ-5D to obtain 
utility values for each child. Utility values for patients under five years were estimated 
through mapping between the EQ-'DQG3HGV4/ ,Q WKLVVWXG\EDVHOLQH(4-5D during 
exacerbation was not collected for ethical reasons. Therefore, asthma symptom scores (ASS) 
at exacerbation were mapped to EQ-' EDVHG RQ H[SHUWV¶ RSLQLRQV 7KH H[SHUW WHDP
comprised of a paediatric consultant and two respiratory nurses who routinely treated 
asthmatic paediatric patients. An EQ-5D health state of 11111 was assigned to ASS scores of 
1-3 in the base case, while ASS scores of 4-6 and 7-9 were mapped to EQ-5D health states of 
22222 and 33333, respectively. In our opinion, the subjective nature of this mapping between 
ASS and EQ-5D was considered to make the EQ-5D scores estimated at the time of 
exacerbation very uncertain. Furthermore, these data would only be relevant to the subgroup 
of patients who have severe acute exacerbations requiring treatment in secondary care as this 
was the population recruited into the MAGNETIC study. This study was blinded to patients, 
healthcare providers and outcome analysts. Therefore, it had low risk of performance and 
detection bias. However, the study was subjected to risk of attrition bias due to the low 
response rate of EQ-5D questionnaires. The authors addressed this limitation by using a 
mapping function to estimate EQ-5D data for WKRVHZKRKDG3HGV4/data. The mapping 
function was based on the subset of patients for whom both PedQL and EQ-5D data were 
available. Following mapping estimations, a total of 218 EQ-5D data were available for 
analysis for the outcome 1 month after exacerbation. 
 
Price et al. (7) included patients in the UK aged between 12 and 80 years with poorly 
controlled asthma at BTS/SIGN treatment Step 2 or 3. Mean age of patients was 44.74 (sd 
16.49) at Step 2 and 50.02 (sd 15.93) at Step 3.  In Step 2 patients, Leukotriene receptor 
antagonist (LTRA) was compared with inhaled corticosteroid (ICS). In step 3 patients who 
were alrHDG\UHFHLYLQJ,&6/75$ZDVFRPSDUHGZLWKORQJDFWLQJȕ-agonist (LABA). EQ-
5D data were directly measured from patients and were presented by treatment steps and 
interventions at baseline, two months and two years. Utility values were estimated using UK 
preferences. This RCT had a high retention rate, with 5-10% loss to follow-up. A large 
proportion (75%) of patients presented with less than four missing data and missing data were 
handled using multiple imputation. This single blinded RCT (n=687) was robust, with large 
sample size, low risk of attrition bias and measured outcomes with EQ-5D. However, utility 
data presented were not stratified by age nor related to asthma exacerbations. Therefore, these 
data lack applicability to the PLEASANT trial and the health states modelled. 
 
Norman et al. (12) evaluated the cost-effectiveness of omalizumab in addition to standard 
care by using a Markov model. Norman et al. (12) used EQ-5D scores measured in the 
EXALT study for day-to-day asthma symptoms. The EXALT study was an open-label RCT, 
which comprised of 404 patients in the UK (age range from 12-75 years) with poorly 
controlled severe allergic asthma (FEV1 <80% predicted). Utility for day-to-day symptoms 
(by treatment arm) was estimated from EQ-5D scores recorded in the EXALT study.    
 
Norman et al. (12) also conducted a systematic review of HRQoL literature to identify 
HRQoL data of relevance to both adult and paediatric populations. In their base case analysis 
they used data from Lloyd et al. (21), a study conducted in an adult population which 
provides estimates of the health utility decrement (loss) associated with exacerbations 
requiring oral steroid treatment and exacerbations requiring hospitalisation. The decrement 
was measured by comparing baseline EQ-5D values to those reported at 4 weeks for patients 
who did and did not experience exacerbations during that 4 week period. They cited another 
study by Steuten et al. (22), which also provided utility values for exacerbations in an adult 
population. However, this study collected data at 3 to 6 month intervals which could make it 
harder to detect the relationship between short term exacerbations and health utility than the 4 
week interval used by Lloyd et al. (21). 
 
Willems et al. (5) used UK preferences to estimate utility scores for asthmatic patients in the 
Netherlands. Populations comprised of adults (n=53) and children (n=56) with mild to 
moderate asthma (GINA state I to III). EQ-5D questionnaires were completed by carers for 
children under 12 years and self-completed for those aged 12 years and over. There were only 
four children with loss of follow up, and various imputation techniques were applied. Missing 
baseline scores were imputed with mean scores. Quality of life at baseline (usual care, 0.96, 
nurse monitoring, 0.92ZHUHFRQVLVWHQWZLWKWKHJRRGOXQJIXQFWLRQRIWKHVWXG\¶VSRSXODWLRQ
(mean FEV1 above 90% predicted). However, these results were elicited from a non-UK 
population although they did use a UK valuation set. Willems et al. (5) did not examine the 
utility decrement in exacerbation. 
 
Brusselle et al. (8) conducted a one-year cohort study (n=158) to determine the efficacy and 
safety of omalizumab by looking at changes from baseline in a single arm study. The mean 
age of the population studied was 48.17 (sd 17.18) and age ranged from 12 to 83 years. 
Included patients had poorly controlled severe allergic asthma (FEV1 <80% predicted) and a 
past history of exacerbations. The Belgian tariff was applied to the collected EQ-5D data at 
baseline and one year. Only 126 of 158 patients had baseline EQ-5D values and only 67 had 
EQ-5D data at 1 year. Handling of missing data, however, was not reported. This tariff was 
obtained from public preferences in Belgium using visual analogue scale (VAS) valuation 
method (56). However, valuation using VAS is not a choice-based method. In the UK, NICE 
has expressed a preference for using a choice-based method such as TTO over VAS (23). 
Therefore, utility data estimated from this study do not meet the NICE requirement of using a 
choice-based valuation method.   
 
Chiou et al. (9) and Gerald et al. (18) were two USA-based studies that used Paediatric 
Asthma Health Outcome Measure (PAHOM). PAHOM is an asthma-specific preference-
based measure designed for children. It consists of a descriptive system with three 
dimensions: symptoms, emotions and activity. The symptoms dimension is classified to three 
levels of severity while emotions and activity are dichotomous choices to indicate presence or 
absence of problems. Unlike EQ-5D with a recall period of one day, respondents are asked to 
describe health states for the past seven days using PAHOM. The utility value in children is 
calculated as the average utility values over seven days. Preference weights for PAHOM 
were elicited from 114 adults in Seattle, USA, who responded for children. VAS was used to 
value all health states and SG was used to value subset of health states to reduce the cognitive 
burden on respondents. VAS values were transformed into SG values using relative risk 
attitude equation (9).  
 
Chiou et al. (9) used PAHOM to measure utility value in 72 children (aged 7-12 years) with 
diagnosed asthma of at least mild persistent severity. The utility value was measured as 0.83 
(converted SG value). Chiou et al. (9) also reported mean VAS and SG values for patients 
according to asthma severity with SG values of 0.79 for mild or no symptoms, 0.70 for 
moderate and 0.28 for severe. A limitation of this study was the small sample size, which 
may have affected the accuracy and validity of results, particularly for the estimates stratified 
by severity. Values stratified by presence or absence of exacerbation were not reported. 
 
Gerald et al. (18) performed a modelling study on different screening strategies for asthma.  
Decision tree and Markov models for a cohort of children were constructed. The Markov 
model consists of five health states: asthma symptom-free day (ASFD), symptom days, 
exacerbation recovery days, emergency department visits and hospitalisation days. The utility 
value for each health state was derived using PAHOM. PAHOM states were allocated to the 
modelled health states. When several PAHOM states could describe a modelled health state, 
utility values of the relevant states were averaged to estimate a single utility value. For 
H[DPSOH WKUHH WR IRXU3$+20VWDWHVZHUH WKRXJKW WRFKDUDFWHULVH³V\PSWRPGD\V´ LQ WKH
model. The utility values of tKHVHVWDWHVZHUHDYHUDJHGWRGHULYHXWLOLW\YDOXHIRU³V\PSWRP
GD\V´7KHDXWKRUVKLJKOLJKWHGWKDWWKLVDSSURDFKPD\IDLOWRFDSWXUHYDOXDWLRQRI³V\PSWRP
GD\V´DFFXUDWHO\,QRXURSLQLRQWKHVXEMHFWLYHQDWXUHRIWKLVPDSSLQJIURPPRGHOOHGKHDOWK
states to PAHOM states reduces the robustness of these utility estimates. In addition, a 
general concern regarding PAHOM was that this measure was not validated for its 
psychometric properties. Furthermore, validation of the relative risk attitude equation used to 
derive SG values was not performed (9).  
 
Two Canada-based observational studies used HUI as an outcome measure. Juniper et al. (11) 
studied the minimum skills required by children to complete outcome measurements 
unassisted. Paediatric Asthma Quality of Life Questionnaire, Feeling Thermometer, HUI2 
and direct valuation were administered to 52 children aged 7 to 17 years (mean: 12 years) 
with symptomatic asthma (mean FEV1: 85% predicted). The HUI2 Canadian tariff was 
applied to obtain utility values. The mean HUI baseline value for asthma was reported as 0.89 
(sd 0.09).  
 
The six-dimensional version of HUI2 is a common generic outcome measure in children. 
Each dimension has three to five levels allowing 8,000 unique health states to be defined. The 
HUI2 tariff was estimated from a sample of 293 parents of school children in Ontario, 
Canada. Valuations were performed using VAS and three health states were valued with VAS 
and SG. A power function was then derived to map VAS values to SG values and multi-
attribute utility theory was used to derive the valuation functions (20).   
 
Mittmann et al. (10) conducted a cross-sectional study to measure HRQoL of 20 chronic 
GLVHDVHV7KH+8,ZDVDGPLQLVWHUHGWKURXJKLQWHUYLHZWRKRXVHKROGUHVLGHQWV
years) in Canada. HUI3 is an adapted version of HUI2 with additional dimensions and levels. 
HUI3 weights were elicited from a random sample of adults (n=504) in Ontario, Canada. In 
this study, however, the HUI2 scoring algorithm was used for HUI3 data. The mean HUI 
score reported for children (age 12-19 years) with asthma was similar to those reported by 
Juniper et al. (11). 
 
,QPHDVXULQJDQGYDOXLQJFKLOGUHQ¶VKHDOWK1,&( LV OHVVFOHDURQ WKHSUHIHUUHG LQVWUXPHQW
but advises use of a standardised and validated preference-based measure designed for 
children. Although HUI is an example of an instrument that meets the mentioned criteria, the 
HUI data from these studies may not be valid, as the study designs lack rigour. Firstly, the 
small sample size (n=52) recruited by Juniper et al. (11) may introduce inaccuracy to the 
results. Secondly, HUI3 data was inappropriately scored using HUI2 scoring algorithm in the 
study by Mittmann et al. (10) and utility scores estimated were deemed by the authors as 
provisional. Furthermore, neither of these studies reported the utility decrement attributable 
to asthma exacerbation. 
 
Three modelling studies performed mapping to estimate EQ-5D values. Brown et al. (17) 
constructed Markov models to evaluate cost-effectiveness of omalizumab in addition to 
standard care. The utility values for day to day symptoms at baseline and 52 week were 
estimated by mapping mini-AQLQ scores from the ETOPA trial onto EQ-5D, using a 
published algorithm by Tsuchiya et al. (24). The ETOPA trial was a multinational open-label 
trial which recruited 312 patients aged between 12 and 73 years (mean: above 35 years) with 
poorly controlled allergic asthma (mean FEV1 <73% predicted) (25). (NB: Brown et al. (17) 
used data from the subgroup of ETOPA patients with severe disease but baseline 
characteristics are not described for this subgroup so Table 2 provides characteristics for the 
ETOPA trial as a whole). The AQLQ scores were mapped to EQ-5D for patients separated by 
disease state and responder status. The mapping algorithm used by Brown et al. (17)  was 
derived from an RCT of 3,000 adults in the UK with a wide range of asthma severity (24). In 
the RCT used to generate the mapping algorithm, both EQ-5D and AQLQ were collected 
(26). Domains in EQ-5D were found to overlap with those in AQLQ, with correlations 
between 0.56 and 0.65. Six main mapping models and two supplementary models were 
derived using the regression method and were validated using an external dataset. However, 
these mapping functions were associated with large marginal errors and should only be 
considered as second best to direct elicitation of EQ-5D data (20, 24). 
 
Brown et al. (17)  used literature based estimates to model the decrement associated with 
exacerbations as the authors stated that the ETOPA trial collected insufficient patient quality 
of life data during exacerbations. The literature based estimates cited by Brown et al. (17) 
appear to be from an earlier publication of the study by Lloyd et al. (21). 
 
The modelling studies by Briggs et al. (13) and Doull et al. (14) mapped AQLQ scores from 
the 52-week GOAL trial onto EQ-5D values. GOAL was a multinational double-blind RCT 
designed to evaluate efficacy of a combination of fluticasone/salmeterol compared to 
fluticasone in terms of asthma control. The GOAL study comprised of 3,416 patients (mean 
age: >35 years; range: 12-80 years) with uncontrolled asthma (mean FEV1 <80% predicted) 
from 44 countries (27). Asthma control in GOAL was classified by  Briggs et al. (13) using 
the GINA definitions. The classifications were totally controlled (TC), well-controlled (WC), 
not well controlled (NWC) and exacerbation requiring oral steroid or secondary care (X). As 
GOAL only collected AQLQ data, a mapping function obtained through personal 
communication with Macran and Kind was used to transform AQLQ scores to EQ-5D values. 
Subsequently, the utility value for each asthma control health state was derived using 
regression. In the regression model, a UK indicator was added as a dummy variable to adjust 
for UK specific-population. The dependent variable was the utility value while asthma 
control and the UK indicator were the independent variables. All independent variables were 
found to be significant predictors of quality of life. The quality of life data from this study is 
of relevance to the PLEASANT trial. However, the mapping function used in the analysis by  
Briggs et al. (13) was inadequately described by the authors and a published article providing 
more details could not be identified from searches. Therefore, an assessment of mapping 
performance was not possible. 
 
Doull et al. (14) adapted the analysis by Briggs et al. (13) and reclassified asthma control to 
³V\PSWRPIUHH´DQG³ZLWKV\PSWRPV´7RWDOO\FRQWUROOHGDVWKPDZDVFODVVLILHGDV³V\PSWRP
IUHH´ZKLOHRWKHUVWDWHVZHUHFODVVLILHGDV³ZLWKV\PSWRPV´7KHZHHNO\XWLOLW\LQWKH³ZLWK
V\PSWRP´VWDWHZDVHTXLYDOHQW WR WKHZHLJKWHGDYHUDJHRI WKHZHHNO\XWLOLW\LQ:&1:&
and X health states from Briggs et al. (13). Regression was used to estimate the relationship 
between asthma control and quality of life, where quality of life was obtained from mapping 
AQLQ scores to EQ-5D. Asthma control and the UK indicator were entered into the model as 
the independent variables, while weekly utility was entered as the dependent variable. 
6XEVHTXHQWO\ XWLOLW\ IRU WKH ³ZLWK V\PSWRPV´ DQG WKH ³V\PSWRPV IUHH´ KHDOWK VWDWHV ZHUH
estimated from the regression coefficients. As utility data in this study were adapted from 
Briggs et al. (13) which mapped AQLQ scores to EQ-5D using the mapping function by 
Macran and Kind, the validity of mapped data was likewise not assessable.  
 
The method used in Carroll et al. (16) and Rodriguez et al. (15) involved valuation of 
hypothetical health states by parents. Parents were asked to value health states described in 
vignettes by imagining their children affected by those states. Descriptions in vignettes, 
however, differed across studies. Rodriguez et al. (15) developed asthma-specific vignettes 
based on PAHOM (9) and these were validated by expert opinions, whereas  Carroll et al. 
(16) developed general descriptions of 29 health states with the inclusion of time as a factor. 
Rodriguez et al. (15) requested parents (n=76) to value vignettes using SG, while  Carroll et 
al. (16) used SG and time-trade off (TTO) methods in a sample of 4,016 parents (NB: each 
parent only valued 3 of a potential 29 states providing around 415 values per state). Neither 
studies constructed vignettes based on rigorous methods such as a focus group. The lack of 
standardised descriptive systems of vignettes and different valuation methods also resulted in 
a lack of comparability of results between studies. In addition, vignettes are limited to 
specific descriptions of a condition and may not fully reflect all experiences of a patient. 
Therefore, vignettes do not meet the NICE reference case and are considered of little function 
in  economic evaluations (23). In view of the various limitations associated with vignettes, 
utility values from Carroll et al. (16) and Rodriguez et al. (15)  were not considered suitable 
for use in the PLEASANT economic analysis. 
 
3.1 Health state utility values selected for use in the PLEASANT economic analysis 
   
 
The systematic review did not identify any studies that directly measured exacerbation-
related utility decrements in children using preference-based measures. Some studies 
estimated utility decrement via mapping, either subjectively (6, 18), or using an unpublished 
mapping algorithm with insufficient details (13).  
 
The utility values used in the economic evaluation by Briggs et al. (13) appear to be most 
relevant to our proposed model structure as they are reported for relevant health states, 
including an exacerbation state, and have been estimated from a trial population which 
included some children. However, the mapping algorithm used to convert from the condition 
specific HRQoL measure (AQLQ) to the EQ-5D utility score is not from a published source 
and is not described in detail making it difficult to assess its validity. However, if the values 
reported by Briggs et al. (13) are taken at face value, they provide an estimate of the utility 
loss for exacerbation versus total asthma control of -0.216 (SE 0.007). It is possible that some 
patients do not have total asthma control in the absence of an exacerbation and the difference 
between the utility values for the exacerbation state and the not well controlled states is 
smaller at -0.112. The data from Briggs et al. (13) suggest that the utility decrement for 
exacerbation in the average patient is likely to fall in the range of -0.112 to -0.216.  
 
There is a reasonable agreement between the values reported by Briggs et al. (13) and Lloyd 
et al. (21). The utility decrements provided by Lloyd et al. (21) from an adult population are -
0.1 and -0.2 for exacerbations requiring oral steroids and exacerbations requiring 
hospitalisation respectively.  
 
Given the uncertainty regarding the mapping algorithm used by Briggs et al. (13) compared 
to the direct collection of EQ-5D data in Lloyd et al. (21), and the use of data from Lloyd et 
al. (21) in a number of published economic evaluations, we decided to use data from  Lloyd 
et al. (21) as the best estimate for utility decrement associated with an exacerbation in 
children. However, utility decrement from the adult population in  Lloyd et al. (21) may not 
reflect the actual decrement in children due to the differences in asthma experience and 
perception of quality of life between children and adults.  
 
Therefore, data from Briggs et al. (13) have been explored in a sensitivity analysis using the 
difference between the total control state and the exacerbation state (-0.216) to estimate the 
quality of life decrement from exacerbations. This sensitivity analysis is considered to 
provide an upper limit on the utility decrement attributable to exacerbation. 
 
We accept that the estimates provided by Briggs et al. (13) and Lloyd et al. (21) probably 
underestimate the degree of utility loss in children with a severe or life-threatening acute 
exacerbation during the period of hospitalisation. This is because the utility values were not 
measured during the acute exacerbation period itself. In the MAGNETIC study, which 
estimated utility scores in children attending EDs with severe acute asthma, the utility was 
estimated to be reduced from a baseline of 0.88 to 0.516 during the initial acute period giving 
a utility decrement of 0.364. However, in the MAGNETIC trial, this more severe utility 
decrement was only applied until hospital discharge with the average length of hospital stay 
being 1 day. If we apply a decrement of 0.364 for 1 day and assume a loss of 0.2 in the 
remaining 6 days, the average utility loss over the whole week of exacerbation (-0.22) would 
be similar to that reported by Briggs et al. (13). 
 
For patients without an exacerbation we have taken the baseline utility score for the control 
arm of the study by Willems et al. (5) as this provides an estimate based on the child version 
of the EQ-5D valued using the adult UK TTO valuation set. The population was Dutch 
children aged 7 to 18 with GINA severity stage I to III receiving standard outpatient care. 
The value applied to patients without an exacerbation will affect the calculation of absolute 
QALYs in each trial arm of the PLEASANT trial but does not affect the estimation of 
incremental QALY gain which goes into the cost-effectiveness ratio, as the PLEASANT 
study assumes that there is no impact of the letter intervention on survival. Therefore the 
selection of this data source is less critical than that used to determine the decrement 
attributable to exacerbations. The data that have been identified for the PLEASANT 
economic analysis are summarized in Table 7. 
 
 
 
 
 
Table 7: Health state utility values to be applied in PLEASANT 
Health state Health utility 
value 
Description of state from source study Measurement Source 
Base case scenario 
No exacerbation 0.96 (sd 0.07) Average baseline utility across children (n=27) aged 7 to 
18 with GINA severity stage I to III receiving standard 
outpatient care in the Netherlands as part of the control 
arm of an RCT. 
EQ-5D child version (filled out by 
parent for age<12). UK adult TTO 
valuation set  
(5) 
Exacerbation not requiring 
hospitalisation (including 
those managed in ED) 
-0.10 
relative to no 
exacerbation 
Adult patients enrolled in a prospective observational 
study who have moderate or severe asthma (BTS 4 /5) at 
baseline and who have experienced one exacerbation 
requiring oral steroid treatment (without hospitalisation) 
in the previous 4 weeks (n=22)  
EQ-5D UK adult valuation set (21) 
Exacerbation requiring 
hospitalisation 
-0.20  
relative to no 
exacerbation 
Adult patients enrolled in a prospective observational 
study who have moderate or severe asthma (BTS 4 /5) at 
baseline who have experienced one exacerbation 
requiring hospitalisation in the previous 4 weeks (n=5) 
EQ-5D UK adult valuation set (21) 
Sensitivity analysis 
No exacerbation  As per base case As per base case As per base case As per base case 
Any exacerbation  -0.216 relative to 
no exacerbation 
Patients aged over 12 years (including adults) enrolled in 
the GOAL study who experienced an exacerbation 
(defined as deterioration in asthma requiring treatment 
with an oral corticosteroid, or an emergency department 
visit or hospitalisation) 
AQLQ values mapped to EQ-5D 
(valuation set not stated) 
(13) 
 
 
3.0 Discussion 
 
The review identified studies which differed in their objectives, study designs, population and 
outcome measurements which led to variations in the characteristics of the utility data 
provided. Only three studies were confined to children while most recruited mixed-aged 
populations comprised mainly of adults. Of these, only a few studies stratified HRQoL by 
age. Generalising utility from mixed-aged populations to children would disregard the fact 
that children have different perspective on HRQoL than adults (28).  Among children and 
adolescents, utility values may also vary due to differences in cognitive development (29, 
30). Therefore, future studies should stratify HRQoL in children by age groups.   
 
The review focused on utility data which would meet the NICE reference case requirements. 
There were challenges in identifying preference-based utility data in children with asthma, 
particularly EQ-5D. Younger children do not have adequate cognitive ability to comprehend 
EQ-5D which was designed for adults. Thus, studies measuring HRQoL in young children 
relied on carer as proxy in the measurement (5, 6). However, proxy reported values were 
found to differ from those of children especially in chronic diseases such as asthma, since 
parents tend to underestimate the impact of asthma on physical activity of children (30). 
Additionally, valuations of EQ-' ZHUH EDVHG RQ DGXOWV¶ WDULII ZKLFK PD\ QRW UHSUHVHQW
FKLOGUHQ¶VSHUVSHFWLYHRIKHDOWKVWDWHYDOXHV Furthermore, EQ-5D was associated with lack of 
sensitivity in children due to ceiling effects (28). In view of these limitations and the lack of 
EQ-5D data in children with asthma, the systematic review was not constrained to utility 
values derived from EQ-5D, but included values estimated from other preference-based 
measures.  
 
From the review, EQ-5D was used in 5 studies (35.7%), while children specific measurement 
such as HUI and PAHOM which were completed by children were reported at a lesser extent 
(14.3% each). Other validated instrument in children such as CHU-9D and EQ-5D-Y were 
not used in the reviewed studies. Self-reports from a child specific instrument is expected to 
SURYLGHDEHWWHUUHSUHVHQWDWLRQRIFKLOGUHQ¶VTXDOLW\-of-life than proxy reports, but preference 
weights were usually elicited from adults or parents which still may not accurately represent 
FKLOGUHQ¶VSHUVSHFWLYH(28). Further research into the measurement of HRQoL in children is 
required particularly in the development of child-based tariffs. In addition, there is a need to 
standardise outcome measurement in children for the purpose of cross-programme 
comparisons. 
 
None of the studies directly measured the utility decrement due to asthma exacerbation using 
EQ-5D or other preference-based measures. In the absence of a robust estimate on the impact 
of exacerbation on HRQoL for children, utility data from adults identified from the review 
were selected as the best estimates to inform the PLEASANT economic analysis.  
 
This systematic review was performed in accordance to methodological guidance from 
Papaioannou et al. (4). The scope of the review was kept broad to identify preference based 
utility values derived from other instruments than the EQ-5D. A comprehensive search 
strategy with no limitations of publication dates, language or study design was used. 
Nonetheless, non-English language full-texts were excluded during the study selection stage. 
A quality of life filter was adapted to include newly-developed preference-based measures for 
children to increase search sensitivity. In addition, full texts were referred to whenever 
abstracts were unclear as quality of life is seldom mentioned in abstracts. Studies were 
critically appraised for quality, relevance to the PLEASANT economic analysis and NICE 
reference case. This review also serves as a case study on how health state utilities are 
identified, critically reviewed and assessed for relevance to an economic model and the 
preferences of a decision-making body. 
 
A synthesis of health state utility values to improve the precision of estimates was not 
performed because the populations of the included studies were not homogenous and varied 
in outcome measurements. Searching for unpublished studies, citation searches and authors-
based searching was not conducted. However, an extensive search was performed by using 
several electronic databases and screening of reference lists to identify all relevant studies. 
 
Given that published utility data derived using preference-based measure in children with 
asthma were lacking, future studies may consider incorporating utility measurement into the 
study design following recommendations from the ISPOR Task Force on Good Research 
Practices for Collecting Health-State Utility Estimates for Economic Models in Clinical 
Studies. The report is currently under development and will serve as a framework on 
planning collection of high quality data for economic models (31). Researchers should 
consider the ethical aspect of health utility assessment during asthma exacerbation as well as 
the timing of assessment in order to capture the transient effect of the acute event on quality 
of life (31). 
 
4.0 Conclusion 
 
Various outcome measurements were used to measure health utilities in children with asthma. 
However, there is a lack of robust estimates on utility decrement in children with 
exacerbation which met the NICE reference case. Future studies should incorporate collection 
of health state utilities in children with asthma, taking into account the ethical and 
methodological considerations of HRQoL assessment during asthma exacerbation.  
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Appendices 
Appendix 1: Full search strategy 
Search database Search terms 
MEDLINE / EMBASE 
 
1. exp child/ 
2. exp adolescent/ 
3. (adolescen$ or teenager$ or teen$ or preteen$ or pre-teen$ or young$ 
or youth or young one$ or paediat$ or pediat$ or child$ or "young 
people").ti,ab. 
4. 1 or 2 or 3 
5. exp asthma/ 
6. (asthma$ or (asthma$ adj exacerbate$) or "asthma exacerbation").ti,ab. 
7. 5 or 6 
8. 4 and 7 
9. quality adjusted life year/ 
10. quality adjusted life.tw. 
11. (qaly$ or qald$ or qale$ or qtime$).tw. 
12. disability adjusted life.tw. 
13. daly$.tw. 
14. health status indicators/ 
15. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf 
thirty six or shortform thirtysix or shortform thirty six or short form 
thirtysix or short form thirty six).tw. 
16. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or 
shortform six or short form six).tw. 
17. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or 
sftwelve or shortform twelve or short form twelve).tw. 
18. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or 
sfsixteen or shortform sixteen or short form sixteen).tw. 
19. (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or 
sftwenty or shortform twenty or short form twenty).tw. 
20. (euroqol or euro qol or eq5d or eq 5d).tw. 
21. (eq5d child$ or eq 5d child$ or eq5d-youth or eq-5d-y or EuroQol 5D- 
Youth or EQ-5D Youth or eq 5d youth).ti,ab. 
22. (chu-9d or chu9d or Child Health Utility Index 9D).tw. 
23. (asui or Asthma Symptom Utility Index).tw. 
24. (hql or hqol or h qol or HRQoL or hr qol).tw. 
25. (hye or hyes).tw. 
26. health$ year$ equivalent$.tw. 
27. health utilit$.tw. 
28. (hui or hui1 or hui2 or hui3).tw. 
29. disutili$.tw. 
30. rosser.tw. 
31. quality of wellbeing.tw. 
32. qwb.tw. 
33. willingness to pay.tw. 
34. standard gamble$.tw. 
35. time trade off.tw. 
36. time tradeoff.tw. 
37. tto.tw. 
38. (preference-based or preference based).tw. 
39. or/9-39 
40. 8 and 40 
 
COCHRANE 
LIBRARY  
( CDSR, HTA, NHS 
EED) 
 
Search Name:  pop(Children asthma) Utility( adapted) filter10 
Last Saved: 04/07/2014 19:06:48.699 
Description:  revised 4/7/14 (eq-5d youth) - nhs eed, SR, HTA  
 
ID Search  
#1 MeSH descriptor: [Child] explode all trees 
#2 MeSH descriptor: [Adolescent] explode all trees 
#3 (adolescen* or teenager* or teen* or preteen* or pre-teen* or 
young* or youth or young one* or paediat* or pediat* or child* or "young 
people"):ti,ab  
#4 #1 or #2 or #3  
#5 MeSH descriptor: [Asthma] explode all trees 
#6 (asthma* or (asthma*adj exacerbate*) or "asthma 
exacerbation"):ti,ab  
#7 #5 or #6  
#8 #4 and #7  
#9 MeSH descriptor: [Quality-Adjusted Life Years] explode all 
trees 
#10 quality adjusted life:ti,ab  
#11 (qaly* or qald* or qale* or qtime*):ti,ab  
#12 "disability adjusted life":ti,ab  
#13 daly*:ti,ab  
#14 MeSH descriptor: [Health Status Indicators] explode all trees 
#15 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or 
sf thirty six or shortform thirtysix or shortform thirty six or short form 
thirtysix or short form thirty six):ti,ab  
#16 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or 
shortform six or short form six):ti,ab  
#17 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or 
sftwelve or shortform twelve or short form twelve):ti,ab  
#18 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or 
sfsixteen or shortform sixteen or short form sixteen):ti,ab  
#19 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or 
sftwenty or shortform twenty or short form twenty):ti,ab  
#20 (euroqol or euro qol or eq5d or eq 5d):ti,ab  
#21 (eq5d child* or eq 5d child* or eq5d-youth or eq-5d-y or 
EuroQol 5D- Youth or EQ-5D Youth or eq 5d youth):ti,ab  
#22 (chu-9d or chu9d or Child Health Utility Index 9D)  
#23 ("aql-5d" or "Asthma Quality of Life Utility Index- 5d" or 
"Asthma Quality of Life Utility Index- 5 dimension"):ti,ab  
#24 (asui or "Asthma Symptom Utility Index"):ti,ab  
#25 (hql or hqol or h qol or HRQoL or hr qol):ti,ab  
#26 (hye or hyes):ti,ab  
#27 health* year* equivalent*:ti,ab  
#28 health utilit*:ti,ab  
#29 (hui or hui1 or hui2 or hui3):ti,ab  
#30 disutili*:ti,ab  
#31 rosser:ti,ab  
#32 quality of wellbeing:ti,ab  
#33 qwb:ti,ab  
#34 willingness to pay:ti,ab  
#35 standard gamble*:ti,ab  
#36 time trade off:ti,ab  
#37 time tradeoff:ti,ab  
#38 tto:ti,ab  
#39 ("preference-based" or "preference based"):ti,ab  
#40 or/9-39   
#41 #8 and #40 in Cochrane Reviews (Reviews and Protocols), Other 
Reviews, Technology Assessments and Economic Evaluations 
SCHARRHUD 
 
1. asthma* or (asthma*adj exacerbate*) or "asthma exacerbation"/ Any 
field 
Econlit 1. (adolescen$ or teenager$ or teen$ or preteen$ or pre-teen$ or 
young$ or youth or young one$ or paediat$ or pediat$ or child$ or 
"young people").ti,ab. 
2. (asthma$ or (asthma$ adj exacerbate$) or "asthma 
exacerbation").ti,ab. 
3. 1 and 2 
4. quality adjusted life.tw. 
5. (qaly$ or qald$ or qale$ or qtime$).tw. 
6. disability adjusted life.tw. 
7. daly$.tw. 
8. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf 
thirty six or shortform thirtysix or shortform thirty six or short form 
thirtysix or short form thirty six).tw. 
9. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or 
shortform six or short form six).tw. 
10. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or 
sftwelve or shortform twelve or short form twelve).tw. 
11. (euroqol or euro qol or eq5d or eq 5d).tw. 
12. (eq5d child$ version or eq 5d child$ version or eq5d-youth or eq-
5d-y).tw. 
13. (chu-9d or chu9d or Child Health Utility Index 9D).tw. 
14. (aql-5d or Asthma Quality of Life Utility Index- 5d or Asthma 
Quality of Life Utility Index- 5 dimension).tw. 
15. (hql or hqol or h qol or HRQoL or hr qol).tw. 
16. (hye or hyes).tw. 
17. health$ year$ equivalent$.tw. 
18. health utilit$.tw. 
19. (hui or hui1 or hui2 or hui3).tw. 
20. disutili$.tw. 
21. rosser.tw. 
22. quality of wellbeing.tw. 
23. qwb.tw. 
24. willingness to pay.tw. 
25. standard gamble$.tw. 
26. time trade off.tw. 
27. time tradeoff.tw. 
28. tto.tw. 
29. (preference-based or preference based).tw. 
30. or/4-29 
31. 3 and 30 
 
 
 Appendix 2: Quality of life filter 
Source / database Filter 
Original Quality of life (ISSG) 
MEDLINE/EMBASE 
1. value of life/  
2. quality adjusted life year/  
3. quality adjusted life.tw  
4. (qaly$ or qald$ or qale$ or qtime$).tw  
5. disability adjusted life.tw  
6. daly$.tw  
7. health status indicators/  
8. (sf36 or sf 36 or short form 36 or shortform 
36 or sf thirtysix or sf thirty six or shortform thirtysix 
or shortform thirty six or short form thirtysix or short 
form thirty six).tw  
9. (sf6 or sf 6 or short form 6 or shortform 6 or 
sf six or sfsix or shortform six or short form six).tw  
10. (sf12 or sf 12 or short form 12 or shortform 
12 or sf twelve or sftwelve or shortform twelve or 
short form twelve).tw  
11. (sf16 or sf 16 or short form 16 or shortform 
16 or sf sixteen or sfsixteen or shortform sixteen or 
short form sixteen).tw  
12. (sf20 or sf 20 or short form 20 or shortform 
20 or sf twenty or sftwenty or shortform twenty or 
short form twenty).tw  
13. (euroqol or euro qol or eq5d or eq 5d).tw  
14. (hql or hqol or h qol or HRQoL or hr 
qol).tw  
15. (hye or hyes).tw  
16. health$ year$ equivalent$.tw  
17. health utilit$.tw  
18. (hui or hui1 or hui2 or hui3).tw  
19. disutili$.tw  
20. rosser.tw  
21. quality of wellbeing.tw  
22. quality of wellbeing.tw  
23. qwb.tw  
24. willingness to pay.tw  
25. standard gamble$.tw  
26. time trade off.tw  
27. time tradeoff.tw  
28. tto.tw  
29. or/1-28 
A) Adapted Quality of life (ISSG): 
MEDLINE/EMBASE 
 
1. quality adjusted life year/ 
2. quality adjusted life.tw. 
3. (qaly$ or qald$ or qale$ or qtime$).tw. 
4. disability adjusted life.tw. 
5. daly$.tw. 
6. health status indicators/ 
7. (sf36 or sf 36 or short form 36 or shortform 36 or 
sf thirtysix or sf thirty six or shortform thirtysix or 
shortform thirty six or short form thirtysix or short 
form thirty six).tw. 
8. (sf6 or sf 6 or short form 6 or shortform 6 or sf six 
or sfsix or shortform six or short form six).tw. 
9. (sf12 or sf 12 or short form 12 or shortform 12 or 
sf twelve or sftwelve or shortform twelve or short 
form twelve).tw. 
10. (sf16 or sf 16 or short form 16 or shortform 16 or 
sf sixteen or sfsixteen or shortform sixteen or short 
form sixteen).tw. 
11. (sf20 or sf 20 or short form 20 or shortform 20 or 
sf twenty or sftwenty or shortform twenty or short 
form twenty).tw. 
12. (euroqol or euro qol or eq5d or eq 5d).tw. 
13. (eq5d child* or eq 5d child* or eq5d-youth or eq-
5d-y or EuroQol 5D- Youth or EQ-5D Youth or eq 
5d youth).ti,ab. 
14. (chu-9d or chu9d or Child Health Utility Index 
9D).tw. 
15. (aql-5d or Asthma Quality of Life Utility Index- 
5d or Asthma Quality of Life Utility Index- 5 
dimension).tw. 
16. (asui or Asthma Symptom Utility Index).tw. 
17. (hql or hqol or h qol or HRQoL or hr qol).tw. 
18. (hye or hyes).tw. 
19. health$ year$ equivalent$.tw. 
20. health utilit$.tw. 
21. (hui or hui1 or hui2 or hui3).tw. 
22. disutili$.tw. 
23. rosser.tw. 
24. quality of wellbeing.tw. 
25. qwb.tw. 
26. willingness to pay.tw. 
27. standard gamble$.tw. 
28. time trade off.tw. 
29. time tradeoff.tw. 
30. tto.tw. 
31. (preference-based or preference based).tw. 
32. or/1-31 
B) Adapted Quality of Life (ISSG) 
Cochrane  
QOL FILTER  
Search Name: QOL FILTER  - 4/7/14  
Last Saved: 04/07/2014 19:54:10.631 
Description:   
 
ID Search  
#1 MeSH descriptor: [Quality-Adjusted Life 
Years] explode all trees 
#2 quality adjusted life:ti,ab  
#3 (qaly* or qald* or qale* or qtime*):ti,ab  
#4 "disability adjusted life":ti,ab  
#5 daly*:ti,ab  
#6 MeSH descriptor: [Health Status Indicators] 
explode all trees 
#7 (sf36 or sf 36 or short form 36 or shortform 
36 or sf thirtysix or sf thirty six or shortform thirtysix 
or shortform thirty six or short form thirtysix or short 
form thirty six):ti,ab  
#8 (sf6 or sf 6 or short form 6 or shortform 6 or 
sf six or sfsix or shortform six or short form six):ti,ab  
#9 (sf12 or sf 12 or short form 12 or shortform 
12 or sf twelve or sftwelve or shortform twelve or 
short form twelve):ti,ab  
#10 (sf16 or sf 16 or short form 16 or shortform 
16 or sf sixteen or sfsixteen or shortform sixteen or 
short form sixteen):ti,ab  
#11 (sf20 or sf 20 or short form 20 or shortform 
20 or sf twenty or sftwenty or shortform twenty or 
short form twenty):ti,ab  
#12 (euroqol or euro qol or eq5d or eq 5d):ti,ab  
#13 (eq5d child* or eq 5d child* or eq5d-youth 
or eq-5d-y or EuroQol 5D- Youth or EQ-5D Youth 
or eq 5d youth):ti,ab  
#14 (chu-9d or chu9d or Child Health Utility 
Index 9D)  
#15 ("aql-5d" or "Asthma Quality of Life Utility 
Index- 5d" or "Asthma Quality of Life Utility Index- 
5 dimension"):ti,ab  
#16 (asui or "Asthma Symptom Utility 
Index"):ti,ab  
#17 (hql or hqol or h qol or HRQoL or hr 
qol):ti,ab  
#18 (hye or hyes):ti,ab  
#19 health* year* equivalent*:ti,ab  
#20 health utilit*:ti,ab  
#21 (hui or hui1 or hui2 or hui3):ti,ab  
#22 disutili*:ti,ab  
#23 rosser:ti,ab  
#24 quality of wellbeing:ti,ab  
#25 qwb:ti,ab  
#26 willingness to pay:ti,ab  
#27 standard gamble*:ti,ab  
#28 time trade off:ti,ab  
#29 time tradeoff:ti,ab  
#30 tto:ti,ab  
#31 ("preference-based" or "preference 
based"):ti,ab  
#32 or/1-31  
 
 Appendix 3: Reasons for exclusion at titles and abstracts 
Reasons Number of studies excluded 
Aged 18 years and above 175 
Did not publish utility data 197 
Non-asthma population 87 
Non-English papers 8 
Non preference based/ non-utility measure 158 
Publication types 34 
Total  659 
 
 Appendix 4: Reasons for exclusion at full-texts 
Study Reasons for exclusion 
Janse et al., 2005 
Used HUI3 but did not report utility data. Results were presented as percentage similarity in 
outcome measurements between physician and parents 
Mo et al., 2004 
Used HUI3 but did not report utility data. Results were presented as graphical differences of 
quality of life between diseases 
Willems et al., 2009 
Used EQ-5D but did not report utility data. Results were presented as EQ-5D interclass 
coefficients and Spearman coefficients between outcome measures 
Burstrom et al., 2011 
Used direct valuation using EQ-VAS as outcome measure (non±preference based) in Swedish 
children 
Finnell et al., 2012 Utility data was obtained from an included study by Caroll and Downs (2009) 
Brodtkorb et al., 2010 
Utility data was presented as utility changes associated with intervention 
Meadows et al., 2013 
Smith et al., 2004 
Wilson et al., 2010a 
Wilson et al., 2010b 
 
